Mostra el registre parcial de l'element

dc.contributor.authorMateu Subirà, Aina
dc.contributor.authorMartinez-Urrea, Ana
dc.contributor.authorGallego, Clara
dc.contributor.authorGisbert Pérez, Laura
dc.contributor.authorDietl, Beatriz
dc.contributor.authorXercavins, Mariona
dc.contributor.authorLópez-Sánchez, Maria
dc.contributor.authorÁlvarez, Silvia
dc.contributor.authorGarcía Rodríguez, Sergi
dc.contributor.authorRoselló, Toni
dc.contributor.authorPérez, Josefa
dc.contributor.authorCalbo, Esther
dc.contributor.authorBoix Palop, Lucía
dc.date.accessioned2025-10-31T13:03:29Z
dc.date.available2025-10-31T13:03:29Z
dc.date.created2025-06-24
dc.date.issued2025-07-25
dc.identifier.citationMateu Subirá, Aina; Martínez-Urrea, Ana.; Gallego Muñoz, Clara[et al.]. Very Early Transition to Oral Antibiotics in Uncomplicated Enterobacterales Bloodstream Infections: Effectiveness and Impact on Carbon Footprint Saving.ca
dc.identifier.issn2079-6382ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/5115
dc.descriptionThis study has been funded by a 2023 CAREer Grant from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) to LBP.ca
dc.description.abstractBackground/Objective: This study aimed to evaluate the effectiveness of very early oral transition in Enterobacterales bloodstream infections (E-BSIs), identify factors associated with it, compare the effectiveness of different oral options, and assess its economic and ecological benefits. Methods: Retrospective, observational cohort study including monomicrobial E-BSI in clinically stable adult patients by day 3 of bacteremia with oral antibiotic options. Transition to oral antibiotics by day 3 or earlier (early oral (EO) group) was compared to later transition or remaining on intravenous therapy (nEO group). Early oral transition-associated factors were analyzed. Oral high-dose beta-lactams (BLs) were compared to quinolones (QLs) or trimethoprim/sulfamethoxazole (TS). Economic and ecological costs were assessed. Results: Of 345 E-BSI, 163 (47.2%) were in the EO group, characterized by more urinary tract infections (UTIs) and shorter hospital stays. The nEO group had higher Charlson Comorbidity Index (CCI), extended-spectrum beta-lactamase (ESBL) production, greater source control need, and longer time to clinical stability. There were no significant differences in mortality and relapse. UTIs were associated with early oral transition (OR 2.02, IC 95% 1.18–3.48), while higher CCI (0.85, 0.77–0.95), source control need (0.39, 0.19–0.85), longer time to clinical stability (0.51, 0.39–0.66), and ESBL isolates (0.39, 0.19–0.80) hindered this practice. High-dose BLs and QL/TS were equally effective. Early oral transition resulted in 38.794 KgCO2eq reduction and EUR 269,557.99 savings. Conclusions: Very early oral transition at day 3 or before in stable E-BSI patients is effective, eco-sustainable, and cost-effective; UTI is related with the early oral switch, while comorbidities, ESBL production, source control need, or longer time to clinical stability hinder this practice.ca
dc.format.extent14ca
dc.language.isoengca
dc.publisherMDPIca
dc.relation.ispartofANTIBIOTICS-BASELca
dc.relation.ispartofseries14;8
dc.rights© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/ licenses/by/4.0/).ca
dc.rights.urihttps://creativecommons.org/ licenses/by/4.0/
dc.subject.otherEnterobacteralesca
dc.subject.otherBloodstream infectionca
dc.subject.otherOral stepdownca
dc.subject.otherInfección del torrente sanguíneoca
dc.subject.otherReducción oralca
dc.subject.otherInfecció del torrent sanguinica
dc.subject.otherReducció oralca
dc.titleVery Early Transition to Oral Antibiotics in Uncomplicated Enterobacterales Bloodstream Infections: Effectiveness and Impact on Carbon Footprint Savingca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc615ca
dc.identifier.doihttps://dx.doi.org/10.3390/antibiotics14080751ca


Fitxers en aquest element

 

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

© 2025 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license
(https://creativecommons.org/
licenses/by/4.0/).
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com https://creativecommons.org/ licenses/by/4.0/
Comparteix a TwitterComparteix a LinkedinComparteix a FacebookComparteix a TelegramComparteix a WhatsappImprimeix